The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Neurological toxicities associated with chimeric antigen receptor T-cell therapy
Open accessAbstract
Chimeric antigen receptor T cell therapy has become an important tool in the treatment of relapsed and refractory malignancy; however, it is associated with significant neurological toxicity. We characterized the neurological toxicity associated with chimeric antigen receptor T-cell therapy in a consecutive series of 100 patients up to 2 months post transfusion, 28 of whom were obtained from chart review and the others by prospective observation. The underlying neoplasms were lymphoma (74%), myeloma (14%), leukaemia (10%), and sarcoma (2%). The median age of the cohort was 64.5 years old and 39% of patients were female. The most commonly occurring neurological symptoms were encephalopathy (57%), headache (42%), tremor (38%), aphasia (35%) and focal weakness (11%). Focal neurological deficits are frequently observed after chimeric antigen receptor T-cell therapy and are associated with regional EEG abnormalities, FDG-PET hypometabolism, and elevated velocities on transcranial Doppler ultrasound. In contrast, structural imaging was typically normal. As this form of treatment is more widely adopted, recognition of the frequently encountered symptoms will be of increasing importance for the neurologists and oncologists caring for this growing patient population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61602-x · Cited by 21,320
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationChimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
A Reversible Posterior Leukoencephalopathy Syndrome
Hinchey, J., Chaves, C., Appignani, B., Breen, J., Pao, L., Wang, A., Pessin, M. S., Lamy, C., Mas, J.-L., & Caplan, L. R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602223340803 · Cited by 3,340
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Cited by
Hayden, P. J., Roddie, C., Bader, P., Basak, G. W., Bonig, H., Bonini, C., Chabannon, C., Ciceri, F., Corbacioglu, S., Ellard, R., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2021.12.003 · Cited by 442
Yakoub-Agha, I., Chabannon, C., Bader, P., Basak, G. W., Bonig, H., Ciceri, F., Corbacioglu, S., Duarte, R. F., Einsele, H., Hudecek, M., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.229781 · Cited by 365
Cytokines in CAR T Cell–Associated Neurotoxicity
Gust, J., Ponce, R., Liles, W. C., Garden, G. A., & Turtle, C. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577027 · Cited by 264
Delorme, C., Paccoud, O., Kas, A., Hesters, A., Bombois, S., Shambrook, P., Boullet, A., Doukhi, D., Le Guennec, L., Godefroy, N., et al. (2020) · European Journal of Neurology · doi:10.1111/ene.14478 · Cited by 173
hECA: The cell-centric assembly of a cell atlas
Chen, S., Luo, Y., Gao, H., Li, F., Chen, Y., Li, J., You, R., Hao, M., Bian, H., Xi, X., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104318 · Cited by 48
Metadata
- Authors
- Rubin, D. B., Danish, H. H., Ali, A. B., Li, K., LaRose, S., Monk, A. D., Cote, D. J., Spendley, L., Kim, A. H., Robertson, M. S., Torre, M., Smith, T. R., Izzy, S., Jacobson, C. A., Lee, J. W., & Vaitkevicius, H.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-03-19
- Volume
- 142
- Issue
- 5
- Pages
- 1334-1348
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2924908514
- Cited by
- 254
- References
- 31
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neurological toxicities associated with chimeric antigen receptor T-cell therapy. https://app.cochat.ai/papers/10.1093/brain/awz053
- The paper
- Rubin, D. B., Danish, H. H., Ali, A. B., Li, K., LaRose, S., Monk, A. D., Cote, D. J., Spendley, L., Kim, A. H., Robertson, M. S., Torre, M., Smith, T. R., Izzy, S., Jacobson, C. A., Lee, J. W., & Vaitkevicius, H. (2019). Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain. https://doi.org/10.1093/brain/awz053
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.